Amylyx Pharmaceuticals, Inc.
AMLXUnited States
18 filed reports · 307 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
18 reports · Mar 2022 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 14 | 2,040 | Mar 2022 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 4 | 1,560 | Dec 2022 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 253 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 156 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 3, 2026 | 528 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 207 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 122 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 131 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 4, 2025 | 352 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 7, 2024 | 147 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 8, 2024 | 123 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 9, 2024 | 127 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 22, 2024 | 518 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 9, 2023 | 159 | Open |
Financial data
307 concepts · 3,600 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial305 concepts · 3,515 facts · Dec 2020 to Jul 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value27 · Mar 2021 to Jun 2026
- Allocated share based compensation expense27 · Mar 2021 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations27 · Mar 2021 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect27 · Mar 2021 to Jun 2026
- Comprehensive income net of tax27 · Mar 2021 to Jun 2026
- Depreciation27 · Mar 2021 to Jun 2026
- Increase decrease in accounts payable27 · Mar 2021 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets27 · Mar 2021 to Jun 2026
- Investment income interest27 · Mar 2021 to Jun 2026
- Net cash provided by used in financing activities27 · Mar 2021 to Jun 2026
- Net cash provided by used in investing activities27 · Mar 2021 to Jun 2026
- Net cash provided by used in operating activities27 · Mar 2021 to Jun 2026
- Net income loss27 · Mar 2021 to Jun 2026
- Nonoperating income expense27 · Mar 2021 to Jun 2026
- Operating income loss27 · Mar 2021 to Jun 2026
- Other nonoperating income expense27 · Mar 2021 to Jun 2026
- Profit loss27 · Mar 2021 to Jun 2026
- Research and development expense27 · Mar 2021 to Jun 2026
- Share based compensation27 · Mar 2021 to Jun 2026
- Share based compensation arrangement by share based payment award options exercises in period total intrinsic value27 · Mar 2021 to Jun 2026
- Sharebased compensation arrangement by sharebased payment award options vested in period fair value127 · Mar 2021 to Jun 2026
- Stockholders equity (US GAAP)27 · Mar 2021 to Jun 2026
- Common stock shares issued25 · Dec 2021 to Jun 2026
- Costs and expenses25 · Sep 2021 to Jun 2026
Product2 concepts · 85 facts · Dec 2022 to Jun 2026
- Research and development expense excluding acquired in process cost50 · Dec 2023 to Jun 2026
- Chargebacks and Cash Discounts35 · Dec 2022 to Dec 2024
Segments
85 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service7 members · 85 facts
- AMX0035 PSP13 · Dec 2023 to Jun 2026
- Avexitide13 · Dec 2023 to Jun 2026
- Other Programs13 · Dec 2023 to Jun 2026
- Chargebacks And Cash Discounts12 · Dec 2022 to Dec 2024
- Other Rebates Returns Discounts And Adjustments12 · Dec 2022 to Dec 2024
- AMX0035 ALS11 · Dec 2023 to Dec 2025
- Medicaid And Medicare Rebate11 · Dec 2022 to Dec 2024
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 6, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.